A promising biomarker adaptive Phase 2/3 design – Explained and expanded
This short communication concerns a biomarker adaptive Phase 2/3 design for new oncology drugs with an uncertain biomarker effect. Depending on the outcome of an interim analysis for adaptive decision, a Phase 2 study that starts in a biomarker enriched subpopulation may continue to the end without...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2023-12-01
|
| Serie: | Contemporary Clinical Trials Communications |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2451865423001758 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|